Oxford Vaccine Group

EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever

Retrieved on: 
Wednesday, May 25, 2022

EpiVax and MGH release exciting new data on a T cell driven vaccine candidate for Q Fever.

Key Points: 
  • EpiVax and MGH release exciting new data on a T cell driven vaccine candidate for Q Fever.
  • Q Fever is a zoonotic disease caused by Coxiella burnetii bacterial infection.
  • Researchers aim to work closely with regulatory agencies to develop a preclinical testing plan suitable for a T cell-driven vaccine candidate.
  • EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design.

Empowering Clinical Trial Sites to Deliver Better Clinical Data, Faster: Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 26, 2022

TORONTO, April 26, 2022 /PRNewswire-PRWeb/ -- With the clinical research space evolving at lightning speed, clinical trial sponsors and research sites may be overwhelmed when trying to scale and accelerate their trials to collect clinical data quickly and accurately. Enter technology.

Key Points: 
  • Attendees will learn methodologies for technology adoption among sites (clinical research coordinators, clinical data managers, monitors, and biostatisticians) that help reduce burnout.
  • TORONTO, April 26, 2022 /PRNewswire-PRWeb/ -- With the clinical research space evolving at lightning speed, clinical trial sponsors and research sites may be overwhelmed when trying to scale and accelerate their trials to collect clinical data quickly and accurately.
  • In this webinar, a panel of clinical trial experts come together to discuss the role that technology plays in clinical data capture.
  • For more information, or to register for this event, visit Empowering Clinical Trial Sites to Deliver Better Clinical Data, Faster.

Clover’s COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial

Retrieved on: 
Friday, November 26, 2021

Clovers COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), will be assessed as a heterologous booster dose in individuals previously vaccinated with either CoronaVac or recombinant Covid-19 vaccine (AstraZeneca/Fiocruz).

Key Points: 
  • Clovers COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), will be assessed as a heterologous booster dose in individuals previously vaccinated with either CoronaVac or recombinant Covid-19 vaccine (AstraZeneca/Fiocruz).
  • The purpose of this stage is to define the optimal vaccine formulation in comparison to a homologous booster of recombinant Covid-19 vaccine (AstraZeneca/Fiocruz).
  • Homologous boosters of CoronaVac or recombinant Covid-19 vaccine (AstraZeneca/Fiocruz) will be used as controls.
  • Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavaxs CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

Global Respiratory Syncytial Virus Market Size and Epidemiology Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021

The "Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory syncytial virus market held a market size of USD 1,669.5 Million in 2020 and is expected to reach USD 4,202.6 Million by 2027.
  • Respiratory syncytial virus (RSV) is a respiratory virus which affects the lungs and its bronchioles.
  • Synagis is a drug to prevent severe respiratory syncytial virus in children and infants who are at high risk.

Veterinary Vaccines Global Market Report 2021 Featuring Boehringer Ingelheim, Merck Animal Health, Zoetis, Eli Lilly and Co, and Bayer AG - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021

The "Veterinary Vaccines Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Vaccines Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the veterinary vaccines market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, and Bayer AG (Bayer Animal Health).
  • The veterinary vaccines market consists of sales of vaccines and related services which are used for the treatment and prevention of diseases in animals.
  • Veterinary vaccines industry includes entities that produce veterinary vaccines like livestock vaccines and companion animal vaccines.

New study to monitor COVID-19 illness and vaccine safety, effectiveness in children and youth in Canada

Retrieved on: 
Friday, June 11, 2021

Continued surveillance for any vaccine is an important component of ensuring the safety and effectiveness of all vaccines for the general population.

Key Points: 
  • Continued surveillance for any vaccine is an important component of ensuring the safety and effectiveness of all vaccines for the general population.
  • This research study is complemented by ongoing safety monitoring by the Public Health Agency of Canada, Health Canada, and multiple public health organizations.
  • This study, which began on June 1, will build upon the information gathered in our research teams Canadian Paediatric Surveillance Program COVID-19 Study ( CPSP COVID-19 Study ).
  • The Vaccine Surveillance Reference Group (VSRG) supports the monitoring of the safety and effectiveness of COVID-19 vaccines in Canada.

CTT Named 'Best Clinical Trial Site' by World Vaccine Congress

Retrieved on: 
Thursday, May 13, 2021

b'SAN ANTONIO, May 13, 2021 /PRNewswire-PRWeb/ -- Clinical Trials of Texas, Inc. (CTT) was named "Best Clinical Site" at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress.\n"CTT is so honored to be recognized for its vaccine work alongside some of the most prestigious names in the pharmaceutical industry," said President/CEO Kay Scroggins, RN.\nCTT has conducted more than 40 vaccine trials including COVID-19, Influenza, Pneumonia, RSV and Meningitis.

Key Points: 
  • b'SAN ANTONIO, May 13, 2021 /PRNewswire-PRWeb/ -- Clinical Trials of Texas, Inc. (CTT) was named "Best Clinical Site" at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress.\n"CTT is so honored to be recognized for its vaccine work alongside some of the most prestigious names in the pharmaceutical industry," said President/CEO Kay Scroggins, RN.\nCTT has conducted more than 40 vaccine trials including COVID-19, Influenza, Pneumonia, RSV and Meningitis.
  • In 2020, CTT was recognized as a top Latino COVID-19 vaccine enroller in an investigational vaccine study.
  • Minority participation in COVID-19 vaccine trials topped 50%, due to ongoing community outreach efforts.
  • CTT conducts studies across Phases I-IV, working with more than 13 investigators across multiple therapeutic areas such as vaccines, metabolic disorders, women\'s health, mental/behavioral health and devices.\n'

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses

Retrieved on: 
Tuesday, April 27, 2021

The company is collaborating with the Oxford Vaccine Group, part of the team that developed the Oxford-AstraZeneca vaccine, who is leading the Com-COV trial.

Key Points: 
  • The company is collaborating with the Oxford Vaccine Group, part of the team that developed the Oxford-AstraZeneca vaccine, who is leading the Com-COV trial.
  • The trial will help understanding of the effects on the immune response when different combinations of approved COVID-19 vaccines are administered for the first and second immunization doses.
  • The study will also examine how common vaccine reactions, such as fever, are after such \xe2\x80\x9cmixed\xe2\x80\x9d schedules.
  • Peter Wrighton-Smith, CEO of Oxford Immunotec said, \xe2\x80\x9cWe are proud to be partnering with the Oxford Vaccine Group on this critical clinical trial.

Oxford University breakthrough on global COVID-19 vaccine

Retrieved on: 
Monday, November 23, 2020

Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:

Key Points: 
  • Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:
    "These findings show that we have an effective vaccine that will save many lives.
  • Vaccitech is proud to have been a small part of the team, together with Oxford University and AstraZeneca, that moved this vaccine from concept to reality in record time.
  • Professor Louise Richardson, Vice-Chancellor at the University of Oxford, said:
    "This is a great day for the University of Oxford and for universities everywhere.
  • TheVaccitechprime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford.

Enesi Pharma and University of Oxford Collaborate to Target Plague With a Novel ImplaVax®-enabled Adenovirus-based Solid Dose Vaccine

Retrieved on: 
Tuesday, April 9, 2019

OXFORD, England, April 9, 2019 /PRNewswire/ -- Enesi Pharma ("Enesi"), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products and scientists at the world-renowned Oxford Vaccine Group ("OVG") at the University of Oxford, announce they have entered into a collaborative agreement to create and test a solid dose vaccine against plague.

Key Points: 
  • OXFORD, England, April 9, 2019 /PRNewswire/ -- Enesi Pharma ("Enesi"), an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products and scientists at the world-renowned Oxford Vaccine Group ("OVG") at the University of Oxford, announce they have entered into a collaborative agreement to create and test a solid dose vaccine against plague.
  • "We are thrilled to enter this new collaboration with Professor Christine Rollier and the University of Oxford.
  • ImplaVax is a novel formulation and needle-free device technology that enables solid dose vaccine implants to be delivered quickly under the skin.
  • The group is based in the Department of Paediatrics in the University of Oxford at the Oxford Vaccine Centre, Churchill Hospital.